Budesonide (Jorveza)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses budesonide orodispersible tablets (Jorveza), 0.5 mg and 1 mg, oral. Indication: Induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).